Reviews/Targeted Therapy Prostate Cancer/Abiraterone overall survival benefit post-docetaxel in metastatic castration-resistant prostate cancer
Arpi · PC-ARPI-02 · v2
The claim names a specific trial, COU-AA-301, and that trial is in the corpus and reports exactly what the claim states: in men whose metastatic prostate cancer had progressed after docetaxel chemotherapy, adding abiraterone acetate plus prednisone made people live longer than placebo plus prednisone [4]. A later analysis of the same trial, run when more patients had been followed for longer, still found a survival benefit [18], and analyses of patient subgroups and biomarkers from the same trial pointed the same way [19][17][12]. The main limitation the panel noted is that almost all the supporting evidence comes from this one trial, with no separate, independently run placebo-controlled trial in the same setting to confirm it. One real-world registry [3] follows similar patients but has no placebo group, so it cannot test the comparison directly. The benefit was large enough that the trial was stopped early, and although the measured size of the benefit shrank somewhat with longer follow-up, it remained present. Because the claim explicitly names COU-AA-301 and that trial directly delivers the result, the panel treated the evidence as strong despite its concentration in a single study.
The pivotal COU-AA-301 trial [4] randomly assigned 1195 post-docetaxel mCRPC patients 2:1 to abiraterone acetate plus prednisone or placebo plus prednisone and reported overall survival of 14.8 vs 10.9 months (hazard ratio 0.65; 95% CI 0.54 to 0.77; P<0.001). The planned final analysis of the same trial [18] reported updated survival of 15.8 vs 11.2 months (HR 0.74; p<.0001) at a median follow-up of 20.2 months. A visceral-disease subgroup analysis [19] and serum-androgen and circulating-tumor-cell analyses [17][12] of the same trial are concordant, with [12] reporting a significant survival difference (P=.034) between the arms. A real-world registry [3] reports post-docetaxel AAP median OS of 23.4 months but includes no placebo comparator. The contested point: The division is over evidential independence, not direction: every arm of the supporting evidence [4][12][17][18][19] is the single COU-AA-301 trial, and no separately conducted placebo-controlled post-docetaxel RCT in the corpus confirms it. The primary report [4] was an interim analysis unblinded early after preplanned stopping criteria were exceeded (median follow-up 12.8 months), and the effect size attenuated from HR 0.65 to HR 0.74 by the final analysis [18] while remaining significant.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The primary COU-AA-301 report [4] was an interim analysis unblinded early after exceeding preplanned stopping criteria (median follow-up only 12.8 months); early-stopped trials tend to overestimate effect size.
Evidential concentration: [4][12][17][18][19] are all the single COU-AA-301 trial. No independent, separately-conducted placebo-controlled post-docetaxel RCT confirms the result in this corpus; registry data [3] lacks a placebo comparator.
Where it remains uncertain. Nearly all supporting evidence is the same trial [4][12][17][18][19] with no independent confirmatory placebo-controlled RCT, and the primary result came from an early-unblinded interim analysis [4].
Aleatory
The OS benefit is a hazard ratio with a confidence interval (0.54-0.77 at interim [4]); the true effect varies within that random sampling range.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary trial result directly establishing the OS benefit in post-docetaxel mCRPC (COU-AA-301).
“overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001)”
Panel auditInternal validity: high · scope of inference: Men with metastatic castration-resistant prostate cancer who had previously received docetaxel.Key limitations: interim analysis (median follow-up 12.8 months)
Surrogacy analysis of COU-AA-301 corroborating a significant survival difference between arms.
“The abiraterone acetate plus prednisone and prednisone-alone groups demonstrated a significant survival difference (P = .034)”
Panel auditInternal validity: high · scope of inference: Surrogacy of a CTC/LDH biomarker panel for OS within COU-AA-301 post-docetaxel mCRPC patients.Key limitations: survival is a secondary analysis · restricted to 12-week surrogate subset · designed to assess biomarker surrogacy not primary OS
Independent analysis of trial data restating the OS benefit in the exact claim population.
“In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration.”
Panel auditInternal validity: high · scope of inference: Prognostic value of baseline serum androgens for OS in COU-AA-301 post-docetaxel mCRPC patients.Key limitations: focus is serum-androgen prognosis · treatment-effect result is a restatement of the trial · no new primary OS analysis
The abstract reports OS figures (e.g. median OS 27.1 vs 23.4 months) but only AAP-line against AAP-line, never AAP against placebo, so the claim's contrast is absent.
Panel auditInternal validity: low · scope of inference: Routine-practice effectiveness and tolerability of AAP as first- or second-line therapy in mCRPC.Key limitations: observational, no placebo · cohorts differ at baseline · not the claimed contrast
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A large double-blind placebo-controlled RCT reports the exact claimed OS benefit and the final analysis confirms it, so the corpus carries the verdict despite the evidence being concentrated in one trial.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent confirmatory RCT. The entire verdict rests on one trial; reproducibility of the OS benefit in a separately conducted trial is untested in this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An independently sponsored, double-blind, placebo-plus-prednisone-controlled randomized trial of abiraterone acetate plus prednisone in post-docetaxel mCRPC with overall survival as the primary endpoint.
Open question: Does the post-docetaxel overall survival benefit of abiraterone acetate plus prednisone reproduce in a trial conducted independently of COU-AA-301? Why it is still open: Every confirmatory analysis in the corpus [4][12][17][18][19] is COU-AA-301 and the only other source [3] lacks a placebo comparator.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19